<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DISOPYRAMIDE PHOSPHATE</span><br/>(dye-soe-peer'a-mide)<br/><span class="topboxtradename">Napamide, </span><span class="topboxtradename">Norpace, </span><span class="topboxtradename">Norpace CR, </span><span class="topboxtradename">Rythmodan <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Rythmodan-LA <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic, class ia</span><br/><b>Prototype: </b>Procainamide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 150 mg regular and sustained release capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Class IA antiarrhythmic agent with pharmacologic actions similar to those of quinidine and procainamide, although chemically
         unrelated. Disopyramide shortens sinus node recovery time and increases atrial and ventricular effective refractory period
         but has minimal effect on refractoriness and conduction time of AV node or on conduction time of His-Purkinje system or QRS
         duration.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts as myocardial depressant by reducing rate of spontaneous diastolic depolarization in pacemaker cells, thereby suppressing
         ectopic focal activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To suppress and prevent recurrence of premature ventricular contractions (unifocal, multifocal, paired) and ventricular tachycardia
         not severe enough to require cardioversion.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>In combination with other antiarrhythmic drugs to treat or prevent serious refractory arrhythmias. To convert atrial fibrillation,
         atrial flutter, and paroxysmal atrial tachycardia to normal sinus rhythm.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Cardiogenic shock, preexisting 2nd or 3rd degree AV block (if no pacemaker is present); uncompensated or inadequately compensated
         CHF, hypotension (unless secondary to cardiac arrhythmia), hypokalemia. Safe use during pregnancy (category C), lactation,
         or in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Sick sinus syndrome (bradycardia-tachycardia); Wolff-Parkinson-White (WPW) syndrome or bundle branch block, myocarditis or
         other cardiomyopathy, underlying cardiac conduction abnormalities; hepatic or renal impairment; urinary tract disease (especially
         prostatic hypertrophy); myasthenia gravis; narrow-angle glaucoma, family history of glaucoma.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span>
<i>, 100 mg q6h or 200 mg sustained release q12h; &gt;<i>50 kg</i>, 100200 mg q6h or 300 mg sustained release capsule q12h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>, 1030 mg/kg/d in divided doses q6h; <i>14 y</i>, 1020 mg/kg/d in divided doses q6h; <i>412 y</i>, 1015 mg/kg/d in divided doses q6h; <i>1218 y</i>, 615 mg/kg/d in divided doses q6h<br/></i></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Start drug 612 h after last quinidine dose and 36 h after last procainamide dose for patients who have been receiving
            either quinidine or procainamide.
         </li>
<li>Give sustained release capsules whole.</li>
<li>Do not use sustained release capsules in loading doses when rapid control is required or in patients with creatinine clearance
            of <img src="../images/special/lesserorequal.gif"/>40 mL/min.
         </li>
<li>Start sustained release capsules 6 h after last dose of conventional capsule if change in drug form is made.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>  Hypersensitivity (pruritus, urticaria, rash, photosensitivity, <span class="speceff-life">laryngospasm</span>). <span class="typehead">CNS:</span> Dizziness, headache, fatigue, muscle weakness, convulsions, paresthesias, nervousness, acute psychosis, peripheral neuropathy. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension,</span> chest pain, edema, dyspnea, syncope, bradycardia, tachycardia; worsening of CHF or cardiac arrhythmia; <span class="speceff-life">cardiogenic shock, heart block</span>; edema with weight gain. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Blurred vision,</span> dry eyes, increased IOP, precipitation of acute angle-closure glaucoma. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth, constipation,</span> epigastric or abdominal pain, cholestatic jaundice. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Hesitancy </span>and<span class="speceff-common"> retention,</span> urinary frequency, urgency, renal insufficiency. <span class="typehead">Other:</span> Dry nose and throat, drying of bronchial secretions, initiation of uterine contractions (pregnant patient); muscle aches,
      precipitation of myasthenia gravis, <span class="speceff-life">agranulocytosis</span> (rare), thrombocytopenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">anticholinergic drugs</span> (e.g., <span class="classification">tricyclic antidepressants</span>, <span class="classification">antihistamines</span>) compound anticholinergic effects; other <span class="classification">antiarrhythmics</span> compound toxicities; <b>phenytoin,</b>
<b>rifampin</b> may increase disopyramide metabolism and decrease levels; may increase <b>warfarin</b>-induced hypoprothrombinemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 6083% reaches systemic circulation. <span class="typehead">Onset:</span> 30 min3.5 h. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 1.58.5 h. <span class="typehead">Distribution:</span> Distributed in extracellular fluid; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 80% excreted in urine, 10% in feces. <span class="typehead">Half-Life:</span> 410 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Check apical pulse before administering drug. Withhold drug and notify physician if pulse rate is slower than 60 bpm, faster
            than 120 bpm, or if there is any unusual change in rate, rhythm, or quality.
         </li>
<li>Monitor ECG closely. The following signs are indications for drug withdrawal: Prolongation of QT interval and worsening of
            arrhythmia interval, QRS widening (&gt;25%).
         </li>
<li>Monitor for rapid weight gain or other signs of fluid retention.</li>
<li>Lab tests: Baseline and periodic hepatic and renal function tests, blood glucose, and serum potassium. Correct hypokalemia
            or other imbalances before initiation of therapy.
         </li>
<li>Monitor BP closely in all patients during periods of dosage adjustment and in those receiving high dosages.</li>
<li>Monitor I&amp;O, particularly in older adults and patients with impaired renal function or prostatic hypertrophy. Persistent urinary
            hesitancy or retention may necessitate lower dosage or discontinuation of drug.
         </li>
<li>Report S&amp;S of hyperkalemia (see Appendix F); it enhances drug's toxic effects.</li>
<li>Measure IOP before treatment begins in patients with a family history of glaucoma.</li>
<li>Monitor for S&amp;S of CHF.</li>
<li>Discontinue promptly if S&amp;S of agranulocytosis, peripheral neuritis, or jaundice appear (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug precisely as prescribed to maintain regularity of heartbeat. Do not skip or stop medication or change dose without
            consulting physician.
         </li>
<li>Weigh daily under standard conditions and check ankles for edema. Report to physician a weekly weight gain of <img src="../images/special/greaterorequal.gif"/>12
            kg (24 lb).
         </li>
<li>Make position changes slowly, particularly when getting up from lying down because of the possibility of hypotension; dangle
            legs for a few minutes before walking, and do not stand still for prolonged periods. If you feel light-headed, lie down or
            sit down.
         </li>
<li>Do not take OTC medications unless approved by physician.</li>
<li>Avoid exposure to sunlight or ultraviolet light; drug may cause photosensitivity.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not drink alcoholic beverages while taking disopyramide.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>